RxDoctor Payments Data

Robert Collier, MD

Retina Specialist · Tullahoma, TNNPI 1518952597

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Alcon at 49.7% of the total. That places this record below the midpoint for retina specialist clinicians in TN, where the typical reported total is $3,018.

$1,469in general payments, 2019–2025

Across 54 payments — averaging $27.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$731
  • Genentech USA, Inc.$377
  • Regeneron Healthcare Solutions, Inc.$80
  • Apellis Pharmaceuticals, Inc.$68
  • AbbVie$55
  • Astellas Pharma US Inc$30
  • plus $128 from 5 others

What the payments were for

  • Food & beverage$1,469100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,469 in reported general payments places this provider in the 25th percentile of 58 retina specialist providers in Tennessee.

See all retina specialist providers in Tennessee

Medicare billing

Part B allowed, 2024
$2,124,349
Medicare patients
1,005
Services billed
35,900

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate326$9,782
CombiganBrimonidine Tartrate/Timolol28$9,587
LumiganBimatoprost19$9,198
Latanoprost480$3,935
Brinzolamide12$2,791
Ciprofloxacin Hcl248$2,590
Timolol Maleate223$2,578
Travoprost21$2,533
Brimonidine Tartrate39$863
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat63$725
Doxycycline Hyclate25$629
Dorzolamide Hcl36$451
Acyclovir19$360
Ketorolac Tromethamine13$348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCombigan, Lumigan$55$18,78547 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 58 retina specialist providers in Tennessee.

Other retina specialist in Tullahoma

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →